Self-Selection Doubts Are No Friend To Alli As Xenical Heads For Switch Panel

FDA has cited a number of unresolved consumer safety concerns in GlaxoSmithKline's Rx-to-OTC switch application for weight-loss drug Alli (Xenical/orlistat 60 mg) stemming from self-selection issues observed in the drug's actual use study